Professor Sophia Zoungas is an internationally recognised clinician scientist and endocrinologist whose research has had a major impact on the prevention and management of diabetes and its renovascular complications. She is Executive Director, The George Institute for Global Health, Sydney, Australia, with senior clinical appointments at Monash Health. She has led and contributed to landmark international clinical trials, including ADVANCE and ADVANCE ON, which transformed understanding of glucose and blood pressure control in type 2 diabetes and informed global clinical guidelines. Her research focuses on reducing cardiovascular and kidney disease in people with diabetes and improving outcomes through evidence based prevention strategies. Her leadership of the Australian Diabetes Clinical Quality Registry is characterised by a strong focus on patient centred outcomes, real world effectiveness, and rapid translation into policy and clinical care. She has published extensively (>340 papers) in leading journals and is among the world’s most highly cited researchers in diabetes. Professor Zoungas is a Fellow of the Australian Academy of Health and Medical Sciences, Member of the EASD Global Council and a past President of the Australian Diabetes Society.

Richard J MacIsaac is Professor and Director of Endocrinology, Department of Endocrinology & Diabetes, St Vincent’s Hospital Melbourne, Professorial Fellow, The University of Melbourne and Senior Principal Research Associate, St Vincent’s Institute of Medical Research, Melbourne, Victoria

Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington School of Medicine. Dr. Tuttle earned her medical degree and completed her residency in Internal Medicine at Northwestern University in Chicago. She was a fellow in Metabolism and Endocrinology at Washington University in St. Louis. Her Nephrology fellowship training was performed at the University of Texas Health Science Center in San Antonio. Dr. Tuttle’s major research interests are in diabetes, chronic kidney disease (CKD), and cardiovascular-kidney-metabolic (CKM) syndrome. As a clinical and translational scientist, her seminal work in physiological and pre-clinical studies laid a foundation for advancing CKD and CKM therapies. Over more than three decades, she has helped deliver SGLT2 inhibitors and GLP-1 receptor agonists as novel treatments to reduce risks of kidney failure, major adverse cardiovascular events, and premature mortality in populations with and without diabetes. She has also been a leading investigator for other breakthrough therapies for CKD and CKM conditions, including next generation incretin, anti-inflammatory, and aldosterone agents. Additionally, she leads the CURE-CKD Registry of real-world data for CKD, diabetes, and hypertension from >6 million health system patients. Dr. Tuttle served on the inaugural Board of Directors for the Kidney Health Initiative and was chair of the Diabetic Kidney Disease Collaborative, both for the American Society of Nephrology. She has also chaired many initiatives for the National Institutes of Health, the International Society of Nephrology, Kidney Disease Improving Global Outcomes, the National Kidney Foundation, and the American Diabetes Association. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two University of Washington School of Medicine Outstanding Clinical Faculty Awards.